NuGene BioPharma, Inc. Formed For Next Generation Stem Cell Pharmacology

IRVINE, Calif., Feb. 24, 2015 /PRNewswire/ -- NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the maker of age-defying aesthetic products for skin and hair rejuvenation, has formed a new division to focus specifically on stem cell derived treatments that may require FDA approval.

"NuGene is realizing outstanding progress with its skin and hair care products," explained Ali Kharazmi CEO of NuGene. "We now want to deliver our technology to the next level. NuGene BioPharma will seek to acquire and develop intellectual property and products that, subject to FDA approval, treat various conditions based upon stem cell technology that we have already created and are currently marketing."

The company markets and sells a variety of cosmeceutical products based on adipose derived human stem cells and human stem cell media. NuGene has carefully developed its line of products based upon proprietary stem cell technology and intends to expand this into a line of FDA approved pharmaceuticals.

"There are many applications for our stem cell technology that could relieve skin conditions such as burns and acne," continued Kharazmi. "This topical segment of the pharmaceutical industry is a natural extension of our current operations, and we are evaluating near term opportunities that could integrate our technology with currently approved treatments. We will continue to explore avenues that can extend our brand and diversify our revenue streams to add shareholder value."

About NuGene International, Inc.

Nugene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media.   The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments".  The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report.  NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue.  NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations.  The company has two patents pending covering 15 unique applications and inventions.  NuGene's goal is to leverage its extensive knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995.These forward-looking statements generally can be identified by use of phrases or terminology such as "anticipate," "believe," "continue," "could," "hope," "target," "project," "goal," "objective," "guidance," "plan," "potential," "predict," "might," "estimate," "expect," "intend," "may," "seek", "should," "target," "will," "would," "look forward" and other similar words or expressions, or expressions, or the negative of these words or similar words or expressions. Similarly, descriptions of NuGene's objectives, strategies, plans or goals or targets contained herein are also considered forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission from time to time, especially those risks and other matters described under "Risk Factors" within NuGene's Form 8-K filed with the Commission on January 6, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information whether as a result of new information, future events or otherwise. All of the forward-looking statements contained herein speak only as of the date of this release.

Investor/ Media Relations:
Chris Rosgen
Capital Market Relations
(949)481-9739

Logo - http://photos.prnewswire.com/prnh/20150224/177397LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nugene-biopharma-inc-formed-for-next-generation-stem-cell-pharmacology-300040327.html

SOURCE NuGene International, Inc.